Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF ...
By linking these technologies, Fujitsu aims to establish a new materials development workflow that accelerates materials ...
Under its Uvance business model, Fujitsu will leverage the technology developed in these trials to realize secure data ...
AdipoLABs Co., Ltd. and Red & Blue Co., Ltd. from Korea, together with their Malaysian subsidiary, AdipoLABs Healthcare (M) Sdn Bhd, today officially opened the new AdipoLABs regional office for ...
GMG Launches Pre-Order Sales for First to Market Multi Language THERMAL-XR (R) Kit with Electric Spray Gun ...
KAWASAKI, Japan, Dec 1, 2025 - (JCN Newswire) - Fujitsu today announced the launch of "Fujitsu Accelerator Program for SPORTS," a global partner co-creation program aimed at fostering new innovation ...
Community Investment Underway FG Gold has committed 1% of gross revenues to a Community Development Fund, supporting education, healthcare, agriculture, infrastructure and enterprise. Early ...
The company leads in Asia and ranks in top eight globally for on-chain businesses such as node operations, staking, and infrastructure support. HashKey participates in the transaction side of the ...
- Proposed Joint Venture to springboard AcroMeta Lifestyle as a provider for a proprietary AI trade platform. - Platform will move beyond traditional e-commerce by using multi-agent AI to actively ...
DigiTech ASEAN Thailand & AI Connect 2025 reinforces Thailand’s vision to become a leading digital hub of ASEAN, empowering businesses to innovate, compete globally, and build a resilient digital ...
第一期試驗結果顯示，SUL-238於健康老年志願者中具安全性、耐受性良好，並展現穩定藥代動力學特性及高腦脊液滲透率，支持該藥物推進至阿茲海默症及其他神經退化性疾病之後續臨床開發階段。
I期试验结果表明，SUL-238在健康老年志愿者中具有安全性、耐受性良好，并展现出稳定的药代动力学特性及高脑脊液渗透性，支持该药物推进针对阿尔茨海默病及其他神经退行性疾病的进一步临床开发。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback